Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Investor Presentation (February 2022)
22 slides from Scisparc's investor presentation, February 2022
Slide 1: Corporate Presentation
CORPORATE PRESENTATION Nasdaq: SPRC February 2022
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation of SciSparc Ltd. (the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” an
Slide 3: SciSparc
SciSparc NASDAQ: SPRC We are revolutionizing cannabinoid-based treatments by developing proprietary pharmaceuticals that increase patients’ safety by reducing doses while maintaining effectiveness 3
Slide 4: SciSparc at a Glance
SciSparc AT A GLANCE Recent Updates Key Stats • New Leadership since August 2020 • Market Cap: $16.3* • Accelerated R&D activities • Shares Outstanding: 3.1M • Strengthened IP portfolio: New patents granted • Float:2.7M (U.S., Japan and Australia) • Founds raised during the • ReceivedTM (Trademark)
Slide 5: Technology
TECHNOLOGY Platform SCI-110 Platform SCI-160 THC (Tetrahydrocannabinol) + CB2 Receptor (CB2R) Platform SCI-210 CannAmideTM Agonist CBD (Cannabidiol) + CannAmideTM TM > Tourette Syndrome (TS) Pain > Alzheimer’s Disease (AD) > Autism Spectrum Disorder (ASD) and agitation > Status Epilepticus (SE) > Ob
Slide 6: Intellectual Property
INTELLECTUAL PROPERTY Own strong 9 patent families 8 granted patents Additional pending IP portfolio (5 in the U.S.) patent applications (Europe, China Japan and more) 6
Slide 7: Our Methodology
OUR METHODOLOGY Utilizing the Endocannabinoid system to affect the central nervous system (CNS) Combining CannAmideTM* with Different cannabinoids Ideal solution Reducing cannabinoids doses Formulation Maintaining therapeutic efficacy Increasing safety 7 *CannAmideTM - SciSparc proprietary formulati
Slide 8: Market Opportunity
MARKET OPPORTUNITY Tourette Alzheimer’s Syndrome (TS) Status Disease (AD) $80M in 2019 and is expected to reach $98.7M by 2023 Epilepticus The global Alzheimer’s therapeutics market is projected to reach $13.6B by 2027 from $7.4B in 2019 The global epilepsy market size would grow from $8.8B in 2018
Slide 9: 2021-2022 Pre-Clinical & Clinical Achievements
2021- 2022 PRE-CLINICAL & CLINICAL ACHIEVEMENTS SCI–110 for Alzheimer's disease and Agitation - Recruited first patient for the Company’s Phase IIa Entered an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel- Aviv Sourasky Medical Center, in Tel-Aviv, Israel,
Slide 10: FDA & EMA Pharmaceutical Pipeline Status
FDA & EMA PHARMACEUTICAL PIPELINE STATUS COMPOUND THERAPEUTIC AREA PRECLINICAL PHASE I PHASE IIa PHASE IIb PHASE III Phase IIb, SCI – 110 Tourette Syndrome FPI Q2 2022 Alzheimer Disease and Open label study, SCI – 110 Agitation enrollment in progress SCI – 210 First results Status Epilepticus H2 202
Slide 11: SCI-110 for Tourette Syndrome (Phase IIA)
SCI-110 for TOURETTE SYNDROME (TS) PHASE IIA Led by Yale University About: TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities As the currently used medications are managing only a small number of disease symptoms with limited
Slide 12: SCI-110 for TS Phase IIB
SCI-110 for TS PHASE IIB • Objective: to evaluate the efficacy, safety and tolerability of the Company’s proprietary SCI-110 in a randomized, double-blind, placebo controlled, cross- over study • Two medical centers: Hannover Medical School, Hannover, Germany and Tel- Aviv Sourasky Medical Center, T
Slide 13: SCI-110 for Alzheimer's Disease & Agitation
SCI-110 for ALZHEIMER’S DISEASE (AD) & AGITATION Phase IIA About: AD or mixed dementia (AD + Vascular Dementia) accounts for over 2/3 of all dementia(s)* with majority of AD patients' manifest agitation and anxiety Objective: to evaluate the safety, tolerability and efficacy trend of SCI-110 in an o
Slide 14: SCI-210 for Autism Spectrum Disorder
SCI-210 FOR AUTISM SPECTRUM DISORDER (ASD) Phase III* About: ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term "spectrum" in autism spectrum disorder refers to the wide ra
Slide 15: SCI-210 for Status Epilepticus
SCI-210 for STATUS EPILEPTICUS (SE) Status Epilepticus is a seizure that lasts longer than 5 minutes or one in which a person has more than 1 seizure within a 5-minute period, without returning to a normal level of consciousness between episodes There is limited pharmaceutical treatment available fo
Slide 16: SCI-160 for Pain
SCI-160 FOR PAIN An innovative and proprietary CB2 Receptor (CB2R) agonist formulation intended for the treatment of pain. This specific CB2R agonist was synthesized by Professor Raphael Mechoulam, Ph.D. CB2 Receptor specific agonists have been found to be involved in mediating analgesic effects in
Slide 17: SCI-160 Pre-Clinical Results Von Frey
SCI-160 PRE-CLINICAL RESULTS 120 Von Frey 100 In a Von Frey Test, rats were Left/right paw sensitivity ration evaluated for tactile allodynia using a 80 Von Frey Filament 60 (%) Morphine 5mg/kg SCI-160 0.1mg Promising results demonstrate analgesic 40 efficacy is better than morphine 20 0 0 1 3 Study
Slide 18: SCI-160 Pre-Clinical Results Hot Plate
SCI-160 250 Hot Plate PRE-CLINICAL RESULTS Morphine 5mg/kg SCI-160 1mg/kg 200 SCI-160 0.1mg/kg Rats were evaluated for pain response Heat sensitivity (%) normalized to day 0 using a hot plate (52ºC) 150 One more, strong results show analgesic 100 efficacy better than morphine 50 0 0 1 3 6 9 Study da
Slide 19: Management
MANAGEMENT Oz Adler Mr. Adler has experience in a wide variety of managerial, financial, tax and accounting practices. From 2012 to 2017, Mr. Adler was employed as a certified public accountant at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. Mr. Adler CEO, CFO holds a B.A. degree
Slide 20: SciSparc Scientific Advisory Board
SciSparc SCIENTIFIC ADVISORY BOARD Award winning scientists Prof. Raphael Mechoulam A Professor Emeritus of the School of Pharmacy at the Faculty of Medicine of the Hebrew University in Jerusalem A recipient of the Israel Prize Prof. James Leckman A child Psychiatrist at Yale University Served as Di
Slide 21: Why Invest in SciSparc?
WHY INVEST IN SciSparc? Proprietary Technology with cutting-edge drug combinations addressing large global unmet medical needs Two Phase 2 Assets addressing multi-billion markets and a Pending Phase 3* Clinical Trial Attractive valuation & well capitalized to execute 2022 objectives Key strategic pa
Slide 22: Thank You
Thank You U.S. INVESTOR RELATIONS RedChip Companies Inc. 1-800-REDCHIP (733-2447) SPRC@REDCHIP.COM 22